Fails 3 of 8 criteria. S3, pharmacy identification: The weight-loss page refers to compounding partners without naming a dispensing pharmacy, and the company and policy pages do not identify one. 2 more criteria also fail; see the table below.
Telehealth service. Passes 3 of 8 criteria. 2 not verified, counting neither way. Recorded against Standard v1.1.
A telehealth practice offering physician-directed weight-loss programs and individual compounded GLP-1 vials, with separate consultation and product prices published on its storefront.
Operating entity The home, about, terms and privacy pages identify the business as PRIMO Health Partners without printing a separate legal entity name.
PRIMO Health Partners' cpa 2cc product page; PRIMO Health Partners' individual tirzepatide 2cc vial product page; PRIMO Health Partners' initial consultation product page
The evidence behind each disposition in the table above, where it appears, and its date.
S1NOT VERIFIEDThe individual clinical-evaluation question did not resolve from the published material. The weight-loss program is described as physician-directed and nurse-guided, but its public product pages do not explicitly establish an individual clinician evaluation before each drug shipment. The check is open.Source: PRIMO Health Partners' online weight loss programs page.
S2NOT VERIFIEDThe payment-sequence question did not resolve from the published material. The storefront lists individual medication vials and a separate initial consultation. These public pages do not establish whether an evaluation is mandatory before purchase; the payment flow is not evidence for this record. The check is open.Source: PRIMO Health Partners' cpa 2cc product page; PRIMO Health Partners' initial consultation product page.
S3FAILThe weight-loss page refers to compounding partners without naming a dispensing pharmacy, and the company and policy pages do not identify one.Source: PRIMO Health Partners' online weight loss programs page; PRIMO Health Partners' about page; PRIMO Health Partners' terms.
S4FAILThe program discloses use of compounding pharmacies but does not state that the compounded products are not FDA-approved on its program or individual vial pages.Source: PRIMO Health Partners' online weight loss programs page; PRIMO Health Partners' cpa 2cc product page.
S5FAILNo certificate of analysis or equivalent lot document is published with the individual vials or weight-loss program.Source: PRIMO Health Partners' online weight loss programs page; PRIMO Health Partners' cpa 2cc product page.
S6PASSThe terms and privacy policy list 800 Battery Avenue SE, Suite 3130, Atlanta, GA 30339.Source: PRIMO Health Partners' terms; PRIMO Health Partners' privacy policy.
S7PASSThe 2.65 mg, 2 cc semaglutide product lists a sale price of $529 with $599 crossed out. The individual 2 cc tirzepatide vial lists $649 with $675 crossed out. These are vial prices, not verified monthly treatment totals; the separate initial consultation is $99.Source: PRIMO Health Partners' cpa 2cc product page; PRIMO Health Partners' individual tirzepatide 2cc vial product page; PRIMO Health Partners' initial consultation product page.
S8PASSNo FDA warning letter names PRIMO Health Partners, and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.